A novel strategy for the therapeutic vaccination of hepatitis C Virus using adenoviral vectors

使用腺病毒载体进行丙型肝炎病毒治疗性疫苗接种的新策略

• 批准号: G0701694/1
• 负责人: Eleanor Barnes
• 金额: $ 31.86万
• 依托单位: University of Oxford
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2009
• 资助国家: 英国
• 起止时间: 2009 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0701694%2F1
• 关键词: novel; strategy; therapeutic; vaccination; hepatitis

Hepatitis C virus currently infects 180 million people world-wide and 1% of the population in the United Kingdom. The majority of people that become infected do not clear the virus from the body and approximately 20% of people will develop severe liver scarring (cirrhosis) and may require liver transplantation. One of the main reasons why people do not get rid of hepatitis C is that the immune system does not see and attack the virus. The current best treatment is called combination therapy. This treatment has many side effects, involves weakly injections and has to be given for a year in many patients. At the end of this treatment less than half of patients get rid of the virus. Our aim is to develop a vaccine that is given to patients before or during combination therapy so that more patients will get rid of the virus. To do this we have developed a vaccine that we hope will stimulate the immune system of patients. This vaccine is made from a part of the common cold virus-called adenovirus-and we have put a part of the hepatitis C virus into the cold virus. The adenovirus acts like a carrier to deliver the part of the hepatitis C virus and hopefully turn on the immune system. Importantly, the cold virus and the part of the hepatitis C virus have been altered to that they cannot replicate and themselves cause an infection. However, many people have previously been infected with the cold virus and because of this their immune system may try to attack our vaccine. To get around this problem we are going to use two unusual types of carrier cold vaccines that will not have infected people before. One of these is a cold virus that usually infects only chimpanzees. We are going to test these vaccines in 2007-2008 in people without hepatitis C. In this project we want to give these vaccines to patients with hepatitis C to see if we can turn on the immune system to attack the virus.

丙型肝炎病毒目前感染了全球1.8亿人，占英国人口的1%。大多数被感染的人没有从体内清除病毒，大约20%的人会出现严重的肝瘢痕（肝硬化），可能需要肝移植。人们无法摆脱丙型肝炎的主要原因之一是免疫系统无法看到并攻击病毒。目前最好的治疗方法称为联合治疗。这种治疗有许多副作用，需要弱注射，许多患者必须服用一年。在这种治疗结束时，不到一半的患者摆脱了病毒。我们的目标是开发一种疫苗，在联合治疗之前或期间给予患者，以便更多的患者摆脱病毒。为此，我们开发了一种疫苗，希望能刺激患者的免疫系统。这种疫苗是由普通感冒病毒的一部分制成的，我们将丙型肝炎病毒的一部分放入感冒病毒中。腺病毒就像一个载体，运送丙型肝炎病毒的一部分，并有望打开免疫系统。重要的是，感冒病毒和丙型肝炎病毒的一部分已经改变，它们不能复制，本身会引起感染。然而，许多人以前曾感染过感冒病毒，因此他们的免疫系统可能会试图攻击我们的疫苗。为了解决这个问题，我们将使用两种不寻常的载体感冒疫苗，它们以前不会感染人类。其中一种是通常只感染黑猩猩的感冒病毒。我们将在2007-2008年在没有丙型肝炎的人身上测试这些疫苗。在这个项目中，我们想把这些疫苗给丙型肝炎患者，看看我们是否可以打开免疫系统来攻击病毒。